Study of PETCT Imaging Using Trop2 and EpCAM Targets for Diagnosing Non-Small Cell Lung Cancer and Solid Lung Nodules

What this Trial Is About

Researchers are evaluating the use of Trop2 and EpCAM-specific PETCT imaging to noninvasively visualize the expression levels of these markers in patients with non-small cell lung cancer NSCLC. The study aims to compare this novel targeted PETCT imaging with conventional 18F-FDG PETCT scans in diagnosing and differentiating solid lung nodules. The goal is to better understand the diagnostic value and imaging feasibility of these new tracers in NSCLC patients. Participants diagnosed with solid lung nodules suspected of NSCLC will undergo whole-body immunoPETCT scans 1-2 hours after injection of one of several tracers 68GaGa-NOTA-T4, 68GaGa-NOTA-RT4, 18FF-RESCA-T4, 18FF-RESCA-RT4, 18FF-RESCA-EPCD6, or 68GaGa-NOTA-EPCD6 at doses of 0.05-0.1 mCikg. The imaging results will be visually and quantitatively scored, including tumor uptake measured by maximum standardized uptake value SUVmax. Patients will also have undergone 18F-FDG PETCT and surgical resection or biopsy as per guidelines. During the study, tumor and normal tissue uptake, radiation dosimetry, and diagnostic accuracy including sensitivity and specificity will be assessed within 30 days. Additional follow-up over months to years will evaluate changes in staging, surveillance, restaging, and treatment responses using immunoPETCT. Participants will be monitored through imaging and clinical assessments to understand tracer behavior and diagnostic performance in NSCLC.

Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer